KELLY GAMACHE: Open Payments
NPI 1881086346 · FLINT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$997 in 44 payments from 12 companies in 2025. Trend: 2023 $1,495 · 2024 $1,007 · 2025 $997
Food & beverage: $885Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 7 | $250 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $154 |
| Avadel CNS Pharmaceuticals, LLC | 4 | $97 |
| Otsuka America Pharmaceutical, Inc. | 4 | $97 |
| Neurocrine BioSciences, Inc. | 4 | $81 |
| Axsome Therapeutics, Inc. | 4 | $66 |
| E.R. Squibb & Sons, L.L.C. | 3 | $63 |
| Alkermes, Inc. | 2 | $55 |
| Vanda Pharmaceuticals Inc. | 2 | $51 |
| Lundbeck LLC | 2 | $39 |
Products named: CAPLYTA, AUSTEDO XR, REXULTI, LUMRYZ, INGREZZA, Auvelity, COBENFY, ARISTADA.
Industry payments across MI — which companies pay providers there.
